Introduction
============

It has been estimated that between 0.5% and 0.8% of the general population suffer from a schizoaffective disorder (SAD) \[[@B3]\]. Despite slightly different concepts of the DSM-IV and ICD-10 diagnostic criteria, the core feature of SAD in both manuals is the concurrent or consecutive occurrence of psychotic and affective symptomatology. The ongoing debate whether SAD does really exist or is rather an artificial or intermediate category, particularly arises from the differing SAD diagnostic criteria. In a five-years retrospective study of 61 patients with initial diagnosis of SAD a proportion of 37 patients shifted to the diagnosis of bipolar disorder (BD) during the observational period \[[@B36]\]. Consequently, Marneros and Goodwin \[[@B30]\] suggested an adaptation of the ICD-10 classification and to subsume SAD to the affective category rather than to the spectrum of schizophrenia (SZ).

It is further known that cognitive impairment is a characteristic feature of SAD and considered to be a core symptom of both BD and SZ. Cognitive deficits are neither exclusively a result of the affective symptomatology nor solely a consequence of pharmacological treatment \[[@B20]\].

Most of the studies concerning cognitive functioning have shown cognitive deficits in bipolar depression. In recent years, persistent cognitive deficits have been reported even in euthymia in about one third of bipolar patients \[[@B19]\]. Patients with BD exhibit a reduced verbal \[[@B51]\] and spatial working memory \[[@B16]\]. Even when controlled for age, premorbid IQ or residual depressive symptomalogy, the performance is poorer concerning learning, short and delayed recall as well as recognition tasks \[[@B32]\]. The verbal recovery of information best predicts the outcome of psychosocial functioning of bipolar patients, and consequently correlates with serious occupational or relational problems \[[@B31]\]. However, Clark, Iversen and Goodwin \[[@B9]\] also controlled for mild affective symptoms and found a reduced sustained attention, only. A reduced selective attention was evaluated using the Stroop Word Colour Test \[[@B50]\]. Moreover, severe deficits in executive dysfunction were observed in many studies. A prolonged planning time \[[@B40]\], reduced verbal fluency \[[@B22]\] and impaired working memory \[[@B46]\] were the main cognitive domains found in these studies. The result was that the cognitive flexibility was also impaired, and appeared to be distinctive for bipolar patients with psychotic features \[[@B1]\]. Despite these convincing data, cognitive performance is significantly poorer in many, but not all executive tasks, Thompson et al. \[[@B47]\] characterized the patient\'s executive deficit as a generic deficit in controlled processing. A meta-analytic review \[[@B38]\] about cognitive deficits in euthymic BD patients analysed the largest effect size (d ≥ 0.8) for aspects of executive function and verbal learning. On the one hand, bipolar patients were partly aware of these cognitive deficits, on the other, they also showed poorer neuropsychological performance without subjective complaints \[[@B33]\]. Nevertheless, there are BD patients with no neuropsychological deficits. According to recent data approximately half of the patients performed without significant difference to healthy controls \[[@B3]\]. Patients with SZ also suffer from widespread neuropsychological deficits, including speed of processing, attention, working memory, verbal and visual learning as well as reasoning, problem solving and social cognition \[[@B20]\]. The impairment is considered to be more severe in SZ than in BD \[[@B25]\] and is not attenuated when statistically controlled for IQ, which was significantly lower in patients with SZ \[[@B43]\]. Burdick et al. \[[@B7]\] found the neurocognitive performance to be longitudinally more stable in SZ than in BD. The latter showed better symptom remission in a 5-years follow-up, especially in short-term and long-term memory.

Despite the great plenty of studies comparing BD with SZ \[[@B11],[@B18],[@B34]\], only a few studies distinctly compared cognitive deficits of BD patients with SAD patients. Torrent et al. \[[@B48]\] found significant impairment in verbal learning and memory in SAD patients. Glahn et al. \[[@B17]\] reported that SAD patients neither significantly differ from BD patients nor from SZ patients in measures of verbal working memory (spatial delayed response task, forward and backward digit span). Szoke et al. \[[@B45]\] concluded that on the one hand SAD patients closely resemble SZ patients in some of the cognitive domains, on the other hand cognitive deficits are ranging on a continuum from SZ to BD.

It is relevant to mention the negative effect of psychotropic medication on cognition. It is well known, that psychotropic drugs with an antidopaminergic profile (e.g. D2/D3 antagonists) induce on one hand a mesocortical hypodopaminergic state, that is correlated with negative symptoms and cognitive impairment, and on the other hand mesolimbic hyporeactivity that is associated with depressive symptoms.

The aim of our study was to contribute data of cognitive functioning of SAD and BD patients in euthymia further and to evaluate the effect sizes of confounding variables on neuropsycho-logical impairment for both disorders.

Patients and methods
====================

Subjects
--------

The study was conducted at the Department of Psychiatry and Psychotherapy, Ruhr University of Bochum, Germany. Thirty-two Bipolar I and twenty-eight patients with Schizoaffective disorder of either gender aged between 18 and 75 years were recruited. The wide age range was intended to allow an analysis of a subsample with elder age.

All were euthymic and met the DSM-IV criteria of bipolar or schizoaffective disorder. Diagnoses were confirmed using the Structured Clinical Interview for DSM-IV (SCID). Subjects with disorders that could be related to neuropsychological impairment (e.g. any significant neurological or medical condition, for instance cardiovascular or pulmonary disease, history of head injury, neurodegenerative disorder, mental retardation, substance dependence within the past year, electroconvulsive therapy in the past 6 months, treatment with benzodiazepines) were excluded from the study. No structural brain abnormalities were reported from the history of the patients or from neuroimaging scans.

After clinical remission for at least 3 months, patients were screened for euthymia on the day of neuropsychological testing using Hamilton Depression Rating Scale (HAMD) or Montgomery-Asberg Depression rating Scale (MADRS) and Young Mania Rating Scale (YMRS). All of the raters attended a rater-training and the interrater agreement was substantial (K = 0.71). HAMD scores had to be less than 8 points each, MADRS scores were lower than 12 points. Patients of the SAD sample did not completly fulfill the remission criteria.

With respect to medication patients in the SAD group were less often on a monotherapy with antipsychotics, but did not differ to the BD group concerning combination therapy or the proportion of compounds with D2/D3 receptor antagonistic properties.

All patients gave written informed consent to participate in the study after the procedures had been fully explained. Ethic approval for the study was granted by the ethics committee of the Ruhr University of Bochum. The study was supported by a grant from the Ruhr University of Bochum, Germany (FoRUM).

Neuropsychological assessment
-----------------------------

The neuropsychological test battery was composed of multiple well-established and some innovative instruments: MWT-B, d2-test, TMT, subsection of WAIS-R, VLMT and logical memory test.

*Estimated premorbid intelligence, MWT-B*\[[@B26]\]: In a 37-item task, the patients had to identify one right word out of four artificial words. This measure delivers an estimate of current intellectual function and a clue to premorbid intelligence.

*Attention, psychomotor speed and cognitive flexibility, d2- test*\[[@B6]\]: A presentation of 47 letters (d or p) with two bars above or under a letter in 14 consecutive rows. Patients have to pass through a row within a time frame of 20 seconds. Parameters are speed (all marked letters, GZ), accurateness (F%) and concentration performance (number of correct marks and less confusion mistakes, KL).

*Trail making test, TMT*\[[@B27],[@B35],[@B37]\]: Part A is a measure for psychomotor speed, part B is used to measure executive functioning and reflects the ability to shift strategy and visuospatial working memory.

*Declarative memory and verbal learning, digit span and block span subtest, subsection of Wechsler Adult Intelligence Scale*\[[@B49],[@B21]\]: Subjects have to repeat a fixed random series of verbal (digit) and visual (block) numbers of increasing length in direct (forward) and reverse (backward) order. Auditory attention, visual attention and short-term retention capacity are assessed in addition to the ability to manipulate the information in the verbal and visual working memory.

*Verbal Learning Memory Test, VLMT*\[[@B23]\]: The VLMT is an equivalent to the Auditory Verbal Learning Test (AVLT) and comprises a list-learning task of 15 semantic independent words. It contains five immediate free recall trials of a list A, which provides a global measure of learning performance. An interference list B is presented afterwards and a short-delay recall of list A in free form is required. After a time span of 20 minutes, list A is repeatedly questioned (long delay free recall).

*Logical memory, emotional versus neutral text samples*\[[@B8]\]: For resolving the question whether patients benefit from an emotional content of an information in terms of a higher reproduction performance in comparison to a neutral text. Recognition ability of both sixteen item versions is recorded.

Statistical analyses
--------------------

Baseline demographic measures and clinical characteristics (Table [1](#T1){ref-type="table"}) were compared between bipolar and schizoaffective patients using one-way analyses of variance (ANOVA) and Chi-square tests. Performance on neuropsychological tests was compared by means of multivariate analyses of covariance (MANCOVA).

###### 

Demographic and clinical characteristics of 32 bipolar and 28 schizoaffective disorder patients

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Demographic and clinical variables              Bipolar disorder patients (n = 32)   schizoaffective\   ANOVA                                  
                                                                                       patients\                                                 
                                                                                       (n = 28)                                                  
  ----------------------------------------------- ------------------------------------ ------------------ -------- ------- ---------- ---------- ---------
  **Age**                                         48.0                                 14.92              45.61    10.5    0.5        1; 58      0.48

  **YMRS score**                                  2.34                                 2.67               7.63     6.37    18.29      1; 57      \< 0.01

  **HAMD score**                                  4.5                                  2.81                                                      

  **MADRS score**                                                                                         10.87    8.01                          

  **Years since having a pychiatric diagnosis**   11.56                                9.61               21.39    11.34   12.04      1; 53      \< 0.01

  **MWT-B score**                                 114.69                               15.54              104.64   16.13   5.98       1; 58      0.02

                                                  **n**                                **%**              **n**    **%**   **χ^2^**   ***df***   **P**

  **Sex**                                                                                                                                        

   **Male**                                       13                                   40.6               7        25      1.64       1          0.2

   **Female**                                     19                                   59.4               21       75                            

  **Education:**                                                                                                                                 

   **No school**                                  0                                    0                  2        7.7     2.55       1          0.11

   **Only school**                                6                                    18.8               5        19.2    0.002      1          0.96

   **School and futher education**                17                                   53.1               14       53.8    0.003      1          0.96

   **Highschool**                                 9                                    28.1               5        19.2    0.62       1          0.43

  **Current mediacation:**                                                                                                                       

   **AD only**                                    2                                    6.3                0        0       1.75       1          0.19

   **MS only**                                    3                                    9.4                7        25.9    2.85       1          0.09

   **NL only**                                    6                                    18.8               0        0       5.83       1          0.02

   **AD & MS**                                    11                                   34.4               3        11.1    4.38       1          0.04

   **AD & NL**                                    7                                    21.9               4        14.8    0.48       1          0.49

   **MS & NL**                                    16                                   50                 16       59.3    0.51       1          0.48

   **All**                                        7                                    21.9               2        7.4     2.37       1          0.12

   **Neither**                                    1                                    3.1                2        7.4     0.56       1          0.46

  **Last episode:**                                                                                                                              

   **Maniac**                                     18                                   56.3               16       57.1    0.01       1          0.94

   **Depressiv**                                  11                                   34.3               4        14.3    3.21       1          0.07

   **Mixed**                                      3                                    9.4                5        17.9    0.93       1          0.34
  --------------------------------------------------------------------------------------------------------------------------------------------------------

ANOVA = Analysis of Variance; YMRS = Young Mania Rating Scale; HAMD = Hamilton Depression Rating Scale; MWT-B = Estimated premorbid intelligence; AD = Antidepressants; MS = mood stabilizer; NL = Antipsychotics

All demographic and clinical variables, which were found to be significantly different between these two groups, were included in the analyses as covariates. Consecutively, one-way analyses of covarinace (ANCOVA) were used to detect group differences with single test dimenions. Estimates of effect size were calculated for untransformed data with the formula

$\frac{\mathbf{\mu}_{\mathit{bipolar}}\textsf{~-~}\mathbf{\mu}_{\mathit{schizoaffective}}\textsf{~}}{\mathbf{\sigma}_{\mathit{pooled}}} = \mathit{d.}$\[[@B24]\]

Additionally, a stepwise regression analysis was conducted in order to assess the association of clinical and demographic variables with cognitive functioning. Age, gender, years since having a psychiatric diagnosis, hospitalisation rate, number of outpatient treatments, pre-morbid IQ, YMRS scores, HAMD score resp. MADRS score and current medication were used as variables.

In order to prevent an apha-inflation due to multiple testing, only results with a significance level at *P*\< 0.01 were interpreted. Having stated no a-priori hypothesis regarding the direction of differences only two-tailed significance tests were computed. Data analysis was performed using Statistical Packages for Social Sciences (SPSS) version 14.0 \[[@B44]\].

Results
=======

Demographic measures and clinical characteristics
-------------------------------------------------

Sociodemographic and clinical variables are summarized separately for 32 Bipolar I and 28 schizoaffective patients (Table [1](#T1){ref-type="table"}). Groups were well matched in terms of age, gender ratio, education and the type of the last episode. The duration of illness differed significantly between the SAD (21,39 years) and BD (11,56 years) group. Gender differences were obvious in both groups with the highest rate of females in the SAD sample. Alcohol consumption was comparable between the two groups; only two bipolar patients exhibited mild alcohol abuse. Young Mania Rating Scale scores, years since having a psychiatric diagnosis, pre-morbid IQ and current medication (i.e. frequency of intake of antipsychotics or the combination of antidepressants and mood stabilizers) differed significantly between the two groups. Hence, these variables were included as covariates in the subsequent analyses.

Neurocognitive function
-----------------------

As indicated in Table [2](#T2){ref-type="table"} significant group differences regarding attention and psychomotor speed (Pillai\'s trace *F*= 6.94; *df*= 4;44; *P*\< 0.01) were found, even when controlled for possible confounding variables (i.e. years since having a psychiatric diagnosis, premorbid IQ, YMRS scores and current medication). The distinction between schizoaffective and bipolar patients accounted for 39% of the variance of the perfomance. Consecutively applied ANCOVA revealed that this result entirely arose from significant group differences with the accurateness of the d2 test (*F*= 12.37; *df*= 1;47; *P*\< 0.01). Schizoaffective patients also showed a trend towards a slower psychomotor speed in the TMT-A test when there have been years since having a psychiatric diagnosis (*F*= 6.42; *df*= 1;52; *P*= 0.01) or the YMRS scores (*F*= 4.49; *df*= 1;49; *P*= 0.04) were not used as covariates in the analysis (ANCOVA).

###### 

Neuropsychological testing results (estimated means)

  Test dimension                      Bipolar patients (n = 32)   Schizoaffective patients (n = 28)   MANCOVA/ANCOVA\#                                       
  ----------------------------------- --------------------------- ----------------------------------- ------------------ -------- ------- ------- ---------- ------
  *Attention and psychomotor speed*                                                                                               6.94    4; 44   \< 0.01    
   **d2 speed (GZ)**                  454.60                      106.56                              494.81             102.24   1.12    1; 47   0.30       0.39
   **d2 accurateness (F%)**           14.36                       8.32                                30.50              17.52    12.37   1; 47   \< 0.01    1.18
   **d2 concentration (KL)**          149.57                      58.66                               140.95             63.08    0.16    1; 47   0.70       0.14
   **TMT-A (sec.)**                   42.61                       22.71                               64.21              42.88    2.91    1; 47   0.09\*\*   0.63
  *Declarative memory*                                                                                                            7.27    7; 41   \< 0.01    
   **digit span forward**             9.35                        1.8                                 8.12               2.35     2.83    1; 47   0.10       0.59
   **digit span backward**            6.21                        2.36                                5.65               2.04     0.50    1; 47   0.48       0.25
   **block span forward**             8.50                        2.04                                9.99               2.02     3.96    1; 47   0.05       0.73
   **block span backward**            7.16                        2.19                                5.68               2.41     4.06    1; 47   0.05       0.64
   **VLMT total, trial 1-5**          44.43                       15.66                               34.15              11.75    4.48    1; 47   0.04       0.74
   **VLMT short delay**               2.54                        2.57                                -0.65              1.46     14.28   1; 47   \< 0.01    1.53
   **VLMT long delay**                2.80                        2.82                                2.29               2.96     0.21    1; 47   0.65       0.18
  *Cognitive flexibility*                                                                                                                                    
   **TMT-B (sec.)**                   106.78                      50.52                               139.29             82.79    1.63    1; 43   0.21\*     0.47
  *Neutral/emotive memory*                                                                                                        0.01    2; 46   0.99       
   **emotional memory**               9.39                        3.53                                9.52               3.06     0.01    1; 47   0.92       0.04
   **neutral memory**                 6.72                        3.37                                6.87               3.04     0.02    1; 47   0.90       0.05

ANCOVA = Analysis of Covariance; MANCOVA = Multivariate Analysis of Covariance; *df*= degrees of freedom; TMT = Trail Making Test; VLMT = Verbal Learning Memory Test; **^\#^**with IQ, years since having a psychiatric diagnosis, Young Mania Rating Scale scores, and current medication (antipsychotics; antidepressant & mood stabilizer) as covariates; \*without years since having a psychiatric diagnosis as covariate significant at P \< 0.05; \*\*without YMRS scores or years since having a psychiatric diagnosis as covariates significant at P \< 0.05.

Similar findings resulted with regard to declarative memory. MANCOVA indicated significant group differences (Pillai\'s trace *F*= 6.55; *df*= 5;43; *P*\< 0.01) accounting for a total of 43% of the variance. This finding was mainly due to the significant lower performance of the patients with a schizoaffective disorder in the VLMT short delay test (*F*= 14.28; *df*= 1;47; *P*\< 0.01). Furthermore, additional ANCOVA without the covariate of YMRS scores or without \"years since having a psychiatric diagnosis\" revealed a trend towards a smaller digit span in the group of schizoaffective patients (*F*= 4.68, *df*= 1;52; *P*= 0.04).

This notwithstanding, no significant group scores were found with regard to cognitive flexibility and neutral resp. emotive memory. Again, an ANCOVA with the covariate \"*years since having a psychiatric diagnosis*\" detected a trend towards less cognitive flexibility (TMT-B) in the group of schizoaffective patients (*F*= 6.93, *df*= 1;47; *P*= 0.01).

Association of demographic and clinical variables on cognitive functioning
--------------------------------------------------------------------------

By means of a stepwise regression analyses variables of potentially influencing cognitive functioning were assessed separately for schizoaffective and bipolar patients. The effect of age, gender, years since having a psychiatric diagnosis, hospitalisation rate, outpatient treatment, premorbid IQ, Young Mania Rating Scale scores and current medication were considered as variables.

In the group of bipolar patients, all neuropsychological tests of attention and psychomotor speed were best predicted by age, with a maximum of 51% of the variance explanation of d2 accurateness (cf. Table [3](#T3){ref-type="table"}). Results of the declarative memory age as well as medication were important variables for the tests. The use of combined antidepressants and mood stabilizers together with the age accounted for 68% of the variance concerning the block span backward. The intake of mood stabilizers predicted best the results of VLMT long delay task, explaining 25% of the variance. The patients\' age was one of the most relevant influencing variables in the TMT-B test.

###### 

Regression coefficients of the regression analyses in bipolar patients

  Dependend variable                  Predictor                           Standardized Beta   t       R^2^
  ----------------------------------- ----------------------------------- ------------------- ------- ------
  *Attention and psychomotor speed*                                                                   
   **d2 speed (GZ)**                  Age                                 -0.60               -3.74   0.36
   **d2 accurateness (F%)**           Age                                 0.58                3.57    0.34
   **d2 concentration (KL)**          Age                                 -0,72               -5.13   0.51
   **TMT-A (sec.)**                   Age                                 0.64                4.15    0.41
  *Declarative memory*                                                                                
   **digit span forward**             Age                                 -0.52               -3.05   0.27
   **block span backward**            Antidepressants & mood stabilizer   -0.58               -4.63   0.68
                                      Age                                                     -3.30   
                                                                          -0.41                       
   **VLMT total, trial 1-5**          Age                                 -0.74               -5.46   0.54
   **VLMT long delay**                Mood stabilizer only                -0.50               -2.89   0.25
  *Cognitive flexibility*                                                                             
   **TMT-B (sec.)**                   Age                                 0.73                5.35    0.53

Only results with p \< 0.01 are depicted.

In the group of schizoaffective patients, less models turned out to be significant. The TMT-A test was best predicted by current use of antidepressants and antipsychotics, explaining 78% of the variance (cf. Table [4](#T4){ref-type="table"}). Patients on antidepressants and mood stabilizers performed worse in the block span forward task and the medication accounted for 48% of the variance. Finally, TMT-B, a test representing cognitive flexibility, was most influenced by age.

###### 

Regression coefficients of the regression analyses in schizoaffective patients

  Dependend variable                  Predictor                           Standardized Beta   t       R^2^
  ----------------------------------- ----------------------------------- ------------------- ------- ------
  *Attention and psychomotor speed*                                                                   
   **TMT-A (sec.)**                   Antidepressants & Antipsychotics    0.88                6.69    0.78
  *Declarative memory*                                                                                
   **block span forward**             Antidepressants & mood stabilizer   -0.69               -3.43   0.48
  *Cognitive flexibility*                                                                             
   **TMT-B (sec.)**                   Age                                 0.74                3.63    0.55

Only results with p \< 0.01 are depicted.

Discussion
==========

The aim of this study was to evaluate neurocognitive functioning of patients with schizoaffective disorder (SAD) and Bipolar I disorder (BD) patients in remission. There have already been a few studies that have analysed the neuropsychological performance between these two diagnostic entities. However, these studies have not yet considered the extent of the differences in neuropsychological test results and significant data was used synonymously for the relevance of the testing results. For this reason SAD patients and BD patients were compared on various neurocognitive test dimensions and the effect sizes were computed. Additionally, the influence of demographic and clinical variables on neuropsychological performance was also analysed separately for each group. The samples differed with respect to psychopathology, premorbid intelligence, duration of illness and gender ratio with a higher proportion of females in the SAD group.

Overall, the data demonstrate that SAD patients have significantly more neuropsychological dysfunction and worse test results concerning the tasks regarding attention as well as declarative memory. An effect size of 1.18 in d2-accurateness resp. 1.53 in the VLMT short delay task, show large effects according to Cohen\'s classification \[[@B10]\]. In the MANCOVA the item \"*years since having a psychiatric diagnosis*\" proved to be an important covariate. Putative significant group differences in the TMT-B test vanished after the comparison was controlled for this variable. This is a remarkable result, taking into account that executive deficits in BD qualify as differential deficits, i.e. that they significantly exceed deficits in other cognitive domains \[[@B47]\]. Thus, regardless of the remarkable dissimilarity the deficits are comparable with regard to the severity. This is in accordance with previous studies investigating SAD with most marked deficits in executive functioning \[[@B5]\].

Our findings replicate the results found by Torrent et al. \[[@B48]\]. They also revealed significantly poorer performance in attention and memory of SAD patients compared to BD patients. Furthermore, in the present study TMT-A and TMT-B test results were significantly different in the ANOVA, but not in the MANCOVA. The putative differing results of Szoke et al. \[[@B45]\] turn out to be also in line with this lack of significance. Although the authors discuss similiar results of subjects with SZ and SAD in the TMT test, there were no significant differences between the groups at all apart from the comparison with the healthy control group. Additionally, they did not check demographic charateristics, though the SAD group had a significantly lower educational level than the BD group. Moreover, the fact that not all tests of declarative memory revealed significant group differences is consistent with the findings of Glahn et al. \[[@B16]\]. They found no significant difference in the digit span task between SAD and BD, albeit they only report the *F*test for bipolar subjects with psychotic features.

The calculated effect sizes indicate a remarkable magnitude of cognitive differences between SAD and BD. The effect sizes for attention (d = 1.18) and declarative memory (d = 1.53) exceed the effect sizes between SZ and BD for the same neurocognitive domain (d = 0.6 resp. d = 0.34) (Seidman et al., 2002). Even the absolut dysfunction of sustained attention and verbal declarative memory in subjects with BD is less stronger (d = 0.69 resp. d = 0.96 compared with healthy controls). Similar effect sizes are reported by Schretlen et al. \[[@B42]\]. Even though there are no significant differences in all of the cognitive domains, a considerable disparity exists in specific cognitive functions. However, these studies did not use the same neuropsychological tests battery as in our study. Seidman et al. \[[@B43]\], for instance, used a dichotomic listening task to assess attentional deficits, whereas the declarative memory was assessed using the Wechsler Memory Scale.

A strength of our study was the careful controlling for the effects of covariates. In the present study the estimated premorbid IQ was lower in the SAD than in the BD sample. Similar findings were reported from Daban et al. (2006), who compared SZ with BD patients. Notably, the worse cognitive functioning of SAD patients persisted, even when controlling for the premorbid IQ \[[@B4],[@B36]\]. It should be noted, that SAD patients had a longer history of diagnosed psychiatric disorder of around 10 years compared to the BD patients, what may be due to a worse clinical course of illness. In this study, we considered the age of onset of the disorder as a covariate.

Furthermore we did not distinguish between psychotic or affective subtypes of schizoaffective disorder, since we primarily included euthymic patients. Retrospectively, it was too vague to rely on the clinical report to differentiate in both of these subgroups.

SAD patients are commonly treated with psychopharmacological agents, e.g. antidepressants, antipsychotic medication or mood stabilizers to improve psychotic or affective symptoms \[[@B29]\]. Significant group differences concerning medication were obvious in our study and, consequently, we considered medication as a confounding variable in our statistical analysis.

Our results regarding the association of demographic and clinical variables on cognitive functioning are in line with the reports in the literature. Dittmann et al. \[[@B12]\] found that age and medication are relevant variables influencing all cognitive domains in BD patients. The negative impact of medication on cognitive performance revealed in our stepwise regression analyses is well in accordance with the study results of Donaldson et al. \[[@B13]\] and Savitz et al. \[[@B41]\]; for differing findings cf. Roiser et al. \[[@B39]\]. There is only sparse data in the literature about cognitive functioning in a separate group of SAD patients. Results for SAD patients are often merged with SZ patients. Recently, Elie et al. \[[@B14]\] reported that antipsychotic medication were associated with poorer cognitive functioning in such a combined group. Our findings convincingly showed a negative impact of medication on cognitive functioning. The variance was explained in up to 78% at maximum in the TMT-B test, what is remarkably a strong effect.

It is to consider that antipsychotic medication with an antidopaminergic profile (e.g. D2/D3 receptor anatgonism) has a strong negative influence on cognitive functioning and depression. In our sample we assumed these special mechanisms of antipsychotics not to be a main factor to explain the differences of cognitive functioning between both groups since SAD patients received no antipsychotic monotherapy, combined therapy did not differ statistically significant between both samples and the ratio of substances with an antidopaminergic profile was not different within the groups. We concluded the effects to be similar in both samples concering the antidopaminergic aspect of medication.

Hence, apart from the mentioned class effects our data did not allow further comments on the influence on cognition of distinct psychotropic compounds. Furthermore, cognitive impairment resulted particularly under medication with combined agents, e.g. concurrent intake of antidepressants, antipsychotics or mood stabilizers.

Finally, to refer to another aspect in the discusseion, Ferrier and Thompson \[[@B15]\] criticised the weakness of many studies not to control for residual affective symptoms. In our study we did not analyse the relevance of affective symptoms, also, because of two different psychometric test scales applied in each sample to evaluate depressive symptomatology (HAMD, MADRS). Nevertheless, the fact that neither HAMD in the BD group nor MADRS in the SAD group significantly correlated with the cognitive performance questions the hypothesis of a strong influence of affective symptoms on cognition in our study sample.

Our results may partly contribute to the discussion of the nosological role of SAD. Basically, there have been three hypotheses discussed in the literature regarding the classification of SAD in relation to SZ and affective disorder \[[@B29]\]. One of the hypotheses suggest that SAD is not a distinct entity at all. According to this hypothesis, the whole category is recommended to be abolished in favour of a broader concept of the other disorders \[[@B28]\]. The second model assumes that SAD only represents the intersection of schizophrenia and affective disorder with no features of its own. Malhi et al. \[[@B29]\] describes SAD to be \"a point on a continuum of affective-psychotic psychopathology\".

Finally, the third hypothesis ascribes SAD to be a distinct entity in the spectrum of psychotic disorder. Our data rather contradicts the assumption of SAD not to exist as an entity. Cognitive impairment is obviously more marked even when controlling the effects of covariates. Whether it is a severe form of BD in the spectrum of affective disorder or a separate entity still remains in discussion.

The main methodological shortcomings of our study are the small sample size and the lack of a healthy control group. The later is of importance as the premorbid IQ was lower in the SAD than in the BD sample. It is to consider that the sample of SAD patients were not completly remitted concerning depressive symptoms. Remission criteria for depression were evaluated using HAMD in the BD group and MADRS in the SAD sample. The use of MADRS in the SAD group resulted of the better item structure and test reliability of MADRS compared to HAMD, but was regretably not applied in the BD sample.

Furthermore, we did not separate between patients with and without a history of psychotic symptoms. Since our sample consisted of euthymic resp. (partially) remitted patients, we did not obtain valid data concerning the clinical history of psychotic symptoms during the lifetime, retrospectively. These limitations may contribute to blur the comparison of neuropsychological test results of SAD and BD patients. Glahn et al. \[[@B17]\] reported on worse results in the spatial delayed response task of BD patients with a lifetime history of psychotic features.

Additionally, future studies should consider the effect of medication in more detail. Due to the limited sample size only a group-wise analysis of psychotropic medication was calculated in our study, albeit marked effects on cognition may result under treatment with certain single compounds. A longitudinal study instead of a cross-sectional design may further contribute to more detailed results.
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